1.BCL2 gene abnormality; poor prognosis for patients; It is an independent prognostic indicator of DLBCLBCL2.
2.Due to overexpression of BCL2 during chemotherapy, the concentration of chemotherapy drugs is reduced, which can enhance the regeneration ability of tumor cells, showing that it is related to patient resistance.
3.BCL2/IGH translocation occurs in 85% of follicular lymphomas and about 1/3 of diffuse lymphoma DL. The prognosis is poor.
4.Differential Diagnosis
Burkitt's lymphoma morphologically suggests a typical age, morphology and immunophenotype. If any of these three characteristics are atypical or have a history of follicular lymphoma, accompanied by MYC breakapart and BCL2 breakapart should be diagnosed as a gray zone lymphoma between Burkitt/DLBCL.